ライフサイエンスコーパス: rotavirus vaccine

1 niversal childhood vaccines (eg, measles and rotavirus vaccines).

2 ntries that were among the early adopters of rotavirus vaccine.

3 4.4%) and 64 099 (25.6%) not vaccinated with rotavirus vaccine.

4 hort of infants who received the pentavalent rotavirus vaccine.

5 within 7 days of getting their first dose of rotavirus vaccine.

6 ompared with infants who did not receive the rotavirus vaccine.

7 ccine, whereas one was related to monovalent rotavirus vaccine.

8 in pathogens following the introduction of a rotavirus vaccine.

9 ing a strategy for the development of future rotavirus vaccine.

10 protection provided by live attenuated oral rotavirus vaccines.

11 evolution may undermine the effectiveness of rotavirus vaccines.

12 strain-specific effectiveness of RV1 and RV5 rotavirus vaccines.

13 ountries and evaluating additional candidate rotavirus vaccines.

14 widely marketed, licensed, live virus, oral rotavirus vaccines.

15 e for monitoring the postlicensure safety of rotavirus vaccines.

16 can infants prior to the introduction of new rotavirus vaccines.

17 cape mutants noted since the introduction of rotavirus vaccines.

18 llance is essential to assess the success of rotavirus vaccines.

19 nation strategies and the next generation of rotavirus vaccines.

20 <5 years of age, before the introduction of rotavirus vaccines.

21 For the pentavalent rotavirus vaccine, 1,301,810 doses were administered dur

22 e significantly less likely to have received rotavirus vaccine (33/44 [73%] unvaccinated) compared wi

23 ssociation between IS and the first licensed rotavirus vaccine, a reassortant-tetravalent, rhesus-bas

24 type distribution were observed based on the rotavirus vaccine administered to infants <1 year of age

25 To facilitate decision making on rotavirus vaccine adoption by countries, help donors pri

26 Effectiveness of 2-3 doses of a rotavirus vaccine against rotavirus requiring emergency

27 declined from 54.8% (95% CI, 48.3%-61.5%) in rotavirus vaccine age-ineligible children to 20.0% (95%

28 ective association exists between receipt of rotavirus vaccine and being hospitalized or visiting the

29 Plasma IgA levels specific for antigens in rotavirus vaccine and oral polio vaccine containing poli

30 ed implementation of existing interventions (rotavirus vaccine and zinc) are needed to prevent diseas

31 re data has identified a causal link between rotavirus vaccines and intussusception in some settings.

32 We review clinical trial data for available rotavirus vaccines and summarize postlicensure data on e

33 ese processes may aid our ability to develop rotavirus vaccines and therapeutics.

34 was present, after accounting for genogroup, rotavirus vaccine, and age.

35 Two effective rotavirus vaccines are available and recommended for rou

36 Second-generation rotavirus vaccines are both highly effective against rot

37 tavirus vaccine introduction that live, oral rotavirus vaccines are effective in high-child-mortality

38 As rotavirus vaccines are implemented, studies have been un

39 As rotavirus vaccines are introduced globally, monitoring i

40 vaccine in an African setting, especially as rotavirus vaccines are introduced into an increasing num

41 Despite successes, oral rotavirus vaccines are less effective in developing coun

42 Safe, effective, and affordable rotavirus vaccines are needed in these countries.

43 anisms for the adaptation and attenuation of rotavirus vaccines are not fully understood.

44 adaptation and in vivo attenuation of human rotavirus vaccines are not known.

45 Rotavirus vaccines are now globally recommended by the W

46 high-mortality settings means that live oral rotavirus vaccines are still likely to provide substanti

47 nd immunogenicity of the P2-VP8-P[8] subunit rotavirus vaccine at different doses in South African to

48 aim is to estimate the efficacy of live oral rotavirus vaccines at each point during follow-up and by

49 RotaTeqTM is a pentavalent rotavirus vaccine based on a bovine rotavirus genetic ba

50 ues to recommend that all US infants receive rotavirus vaccine based on the age and precaution/contra

51 terms of generalizability to routine use of rotavirus vaccine because the analysis was limited to he

52 lable on the safety of the second-generation rotavirus vaccines both in the United States and interna

53 virus may contribute to indirect effects of rotavirus vaccine, but data are lacking from low-income

54 itis have declined since the introduction of rotavirus vaccines, but the burden of norovirus-associat

55 Several nonliving rotavirus vaccine candidates have been evaluated in anim

56 of Rotavac, a monovalent human-bovine (116E) rotavirus vaccine, carried out across 3 sites in India.

57 In contrast to live rotavirus vaccines, CD4(+) T cells were found to be the

58 %) one dose, and 136 (25%) no doses of human rotavirus vaccine, compared with 1434 rotavirus-negative

59 occal conjugate vaccines and live attenuated rotavirus vaccines confer 19.7% (95% confidence interval

60 Rotarix, an orally administered rotavirus vaccine, contained porcine circovirus-1 (PCV1)

61 We sought to determine monovalent rotavirus vaccine cost-effectiveness in Malawi, one of A

62 P[6]-based rotavirus vaccines could broaden protection in such sett

63 Introduction of effective and available rotavirus vaccines could substantially affect worldwide

64 nt interference after completion of the full rotavirus vaccine course.

65 he 2 delivery areas may be due to the varied rotavirus vaccine coverage and presentation rates to the

66 ussus vaccination coverage rates to estimate rotavirus vaccine coverage rates.

67 uncan Steele discuss the evidence supporting rotavirus vaccine deployment in Asian countries.

68 of targeted attenuation for next-generation rotavirus vaccine design.

69 Since the introduction of rotavirus vaccine, diarrhea-associated health care utili

70 4-12 weeks after administration of the last rotavirus vaccine dose.

71 administered with both the first and second rotavirus vaccine doses was found to be positively assoc

72 6 Ghanaian infants after 2-3 doses of G1P[8] rotavirus vaccine during a vaccine trial, by HBGA status

73 end of 2013, the majority of countries using rotavirus vaccine during the review period were low-mort

74 of US children, we observed that RV5 and RV1 rotavirus vaccines each provided a lasting and broadly h

75 l study at 6 public sector sites to estimate rotavirus vaccine effectiveness (VE) in age-eligible chi

76 We sought to evaluate rotavirus vaccine effectiveness (VE) in this setting.

77 Using data from rotavirus vaccine effectiveness (VE) studies, we assesse

78 We evaluated monovalent rotavirus vaccine effectiveness (VE) under conditions of

79 ion of rotavirus strains and strain-specific rotavirus vaccine effectiveness after vaccine introducti

80 wis-negative phenotypes contributes to lower rotavirus vaccine effectiveness in Malawi.

81 Data on rotavirus vaccine effectiveness in sub-Saharan Africa ar

82 inform the evaluation of direct and indirect rotavirus vaccine effects in Africa.

83 Rotavirus vaccine efficacy (VE) estimates in low-resourc

84 phasize the need for continued monitoring of rotavirus vaccine efficacy against emerging rotavirus ge

85 gnificant correlation between IgA titers and rotavirus vaccine efficacy and hypothesize that a critic

86 e used regional rotavirus disease burden and rotavirus vaccine efficacy data, global natural intussus

87 Rotavirus vaccine efficacy is lower and wanes more rapid

88 Rotavirus vaccine efficacy is lower in low-income countr

89 henotype was associated with reduced risk of rotavirus vaccine failure.

90 on cases and mortality potentially caused by rotavirus vaccine for each of the 14 countries and compa

91 orts to develop CDC-9 as a new generation of rotavirus vaccine for live oral or parenteral administra

92 nd tolerability of a monovalent human-bovine rotavirus vaccine for severe rotavirus gastroenteritis i

93 h both their first and their second doses of rotavirus vaccine had 0.63 times the odds of seroconvert

94 While rotavirus vaccine had been introduced in >60 countries w

95 Three doses of BRV-PV, an oral rotavirus vaccine, had an efficacy of 66.7% against seve

96 ction of children who are age-ineligible for rotavirus vaccine has also been observed in some high an

97 Development of live rotavirus vaccines has been highly influenced by views r

98 Implementation of rotavirus vaccines has substantially decreased hospitali

99 and strain changes after the introduction of rotavirus vaccine have been reported.

100 Rotavirus vaccines have a favourable benefit-risk profil

101 Live oral rotavirus vaccines have been developed by serial passagi

102 Since licensure in 2006, rotavirus vaccines have been introduced in more than 100

103 Two rotavirus vaccines have been licensed in >100 countries

104 cine efficacy by duration of follow-up), new rotavirus vaccines have entered the market, vaccine pric

105 Infant rotavirus vaccines have led to substantial reductions in

106 New rotavirus vaccines have now been developed and extensive

107 In these countries, rotavirus vaccines have reduced all-cause diarrhea and r

108 Two well tolerated and effective rotavirus vaccines have reduced the health burden of rot

109 Two new rotavirus vaccines have shown efficacy against severe ro

110 Rotavirus vaccines have suboptimal efficacy in low- to m

111 Current rotavirus vaccines have the potential to greatly reduce

112 Following the conclusion of a human rotavirus vaccine (HRV) cluster-randomized, controlled t

113 mmended schedule for receipt of 2-dose human rotavirus vaccine (HRV) coincides with receipt of the fi

114 bella vaccine (MR) and a third dose of human rotavirus vaccine (HRV; MR + HRV), compared with MR give

115 tiveness of a two-dose schedule of the human rotavirus vaccine (HRV; Rotarix) given early at 6 and 10

116 have received at least one dose of the human rotavirus vaccine (ie, those born after June 14, 2009) a

117 strategies should be evaluated for improving rotavirus vaccine immunogenicity in high burden countrie

118 ding concomitant receipt of OPV, that affect rotavirus vaccine immunogenicity in high- and low-child-

119 concomitantly with rotavirus vaccine reduced rotavirus vaccine immunogenicity.

120 Further studies are needed of the rotavirus vaccine impact after the nationwide introducti

121 MA) to identify observational evaluations of rotavirus vaccine impact among children <5 years of age

122 rotavirus in Rwanda fell substantially after rotavirus vaccine implementation, including among older

123 should encourage countries still considering rotavirus vaccine implementation.

124 pilot introduction of the Rotarix live, oral rotavirus vaccine in all public health facilities in Lus

125 g and establishes the public health value of rotavirus vaccine in an African setting, especially as r

126 6%, 80%, and 86% received 1 or more doses of rotavirus vaccine in each year from 2007 to 2010.

127 he vaccine effectiveness of monovalent human rotavirus vaccine in preventing admission to hospital fo

128 vaccine effectiveness of 1 or more doses of rotavirus vaccine in preventing rotavirus gastroenteriti

129 Together with the demonstrated impact of rotavirus vaccine in reducing population hospitalization

130 tions raise concerns regarding the safety of rotavirus vaccine in severely immunocompromised patients

131 Successful implementation of any rotavirus vaccine in the developing world requires addit

132 ffects of pneumococcal conjugate vaccine and rotavirus vaccine in the estimation.

133 In countries that had not introduced rotavirus vaccine in their national immunisation program

134 on issued a global recommendation for use of rotavirus vaccines in 2009.

135 re to assess the real-world effectiveness of rotavirus vaccines in a range of settings.

136 WHO recommends routine use of rotavirus vaccines in all countries, particularly in tho

137 l evidence of the population-level impact of rotavirus vaccines in children <2 years of age in Matlab

138 round the performance of orally administered rotavirus vaccines in developing countries, vaccine impl

139 ody of evidence on the efficacy of live oral rotavirus vaccines in different settings, but these data

140 bout the new introduction and current use of rotavirus vaccines in Gavi countries.

141 level of protection detected for the current rotavirus vaccines in low-income versus high-income sett

142 Experience with routine use of rotavirus vaccines in lower middle income countries has

143 ctiveness of RV5 (RotaTeq) and RV1 (Rotarix) rotavirus vaccines in preventing rotavirus gastroenterit

144 t lower effectiveness and waning immunity of rotavirus vaccines in resource-poor populations.

145 oncerns remain about the performance of oral rotavirus vaccines in these challenging settings.

146 he study period, 207,955 doses of monovalent rotavirus vaccine (including 115,908 first doses and 92,

147 acy stems from studies of previous candidate rotavirus vaccines, including bovine and rhesus rotaviru

148 As global availability of rotavirus vaccines increases, recent studies have assess

149 umented an intussusception risk with current rotavirus vaccines, international data indicate a possib

150 countries in sub-Saharan Africa to introduce rotavirus vaccine into its national immunization program

151 in the Newly Independent States to introduce rotavirus vaccine into its national immunization program

152 ome African country to introduce pentavalent rotavirus vaccine into its routine national immunisation

153 esburg, before and after the introduction of rotavirus vaccine into South Africa's national immunizat

154 006, more than 100 countries have introduced rotavirus vaccine into their immunization programs.

155 For countries that have introduced a rotavirus vaccine into their national immunisation progr

156 recommendation that all countries introduce rotavirus vaccine into their national immunization progr

157 e findings highlight the need to incorporate rotavirus vaccines into immunisation programmes in count

158 Pre-rotavirus vaccine introduction (2009-2011) and post-rota

159 us vaccine introduction (2009-2011) and post-rotavirus vaccine introduction (2013-2014) periods were

160 zed for diarrhea was 40% (IQR, 28-45) before rotavirus vaccine introduction and 20% (IQR, 20-20) 4 ye

161 ur new estimates can be used to advocate for rotavirus vaccine introduction and to monitor the effect

162 mong children; however, the global impact of rotavirus vaccine introduction has not been described us

163 of diarrhea requiring hospitalization after rotavirus vaccine introduction in Africa.

164 tomatic community controls for 4 years after rotavirus vaccine introduction in Malawi.

165 We describe the impact of rotavirus vaccine introduction on admissions for acute r

166 dditional evidence for countries considering rotavirus vaccine introduction that live, oral rotavirus

167 at least 12 months of data before and after rotavirus vaccine introduction were included.

168 Following rotavirus vaccine introduction, a small increase in intu

169 Following rotavirus vaccine introduction, seasonal peaks of rotavi

170 hospitalizations, temporally associated with rotavirus vaccine introduction, was observed in children

171 te watery diarrhea despite a clear impact of rotavirus vaccine introduction.

172 ins poorly characterized, particularly after rotavirus vaccine introduction.

173 ted to children 7-18 weeks of age at time of rotavirus vaccine introduction.

174 n-hospital morbidity and mortality following rotavirus vaccine introduction.

175 ectious etiologies of intussusception before rotavirus vaccine introduction.

176 arrhea deaths captured by HIMS pre- and post-rotavirus vaccine introduction.

177 tes before (2000-2005) and after (2007-2009) rotavirus vaccine introduction.

178 younger than 5 years in GRSN sites following rotavirus vaccine introduction.

179 teritis shifted towards older children after rotavirus vaccine introduction.

180 lacement is a major concern after nationwide rotavirus vaccine introductions.

181 Monovalent human-bovine (116E) rotavirus vaccine is effective and well tolerated in Ind

182 Monovalent rotavirus vaccine is effective in preventing hospitaliza

183 Rotavirus vaccine is effective in preventing rotavirus d

184 Rotavirus vaccine is recommended for routine use in all

185 Live pentavalent human-bovine reassortant rotavirus vaccine is recommended in the United States fo

186 The risk-benefit analysis of rotavirus vaccines is extremely favorable but other stra

187 Efficacy of live oral rotavirus vaccines is reduced in low-income compared wit

188 The efficacy of rotavirus vaccines is variable in settings with differen

189 th Organization European Region to introduce rotavirus vaccine (July 2012).

190 ation formulation, zinc supplementation, and rotavirus vaccines-make now the time to revitalise effor

191 Likelihood of "take" for any particular rotavirus vaccine may differ across populations based on

192 An additional dose of rotavirus vaccine may enhance the immune response and le

193 Parenteral non-replicating rotavirus vaccines might offer benefits over oral vaccin

194 14 Latin American countries currently using rotavirus vaccine must now weigh the health benefits ver

195 Since the introduction of rotavirus vaccines, norovirus has become the leading cau

196 re low-mortality countries and the impact of rotavirus vaccine on global estimates of rotavirus morta

197 Despite the success of rotavirus vaccines over the last decade, rotavirus remai

198 strain replacement after the introduction of rotavirus vaccines, particularly in developing countries

199 Current oral rotavirus vaccines perform suboptimally in resource-poor

200 vides an informative threshold for assessing rotavirus vaccine performance.

201 er current coverage levels, pneumococcal and rotavirus vaccines prevent 23.8 million and 13.6 million

202 The rotavirus vaccine produced in India that we evaluated wa

203 We aimed to assess the impact of the rotavirus vaccine program and estimate vaccine effective

204 coinciding with the introduction of the new rotavirus vaccine program in England.

205 The recent introduction of a rotavirus vaccine program in Mexico to control rotavirus

206 ound direct and herd immunity impacts of the rotavirus vaccine program in young children in the Repub

207 The rotavirus vaccine program is highly cost-effective.

208 The successful introduction of a rotavirus vaccine program was preceded by several decade

209 ether monovalent (RV1) and pentavalent (RV5) rotavirus vaccines provide adequate protection against d

210 This evaluation sought to determine if rotavirus vaccine provided protection through the second

211 Human rotavirus vaccine provided sustained protection against

212 entified all randomised controlled trials of rotavirus vaccines published until April 4, 2018, using

213 ded observational, post-licensure studies of rotavirus vaccines, published from Jan 1, 2006, to Dec 3

214 was that OPV administered concomitantly with rotavirus vaccine reduced rotavirus vaccine immunogenici

215 (OPV), when administered concomitantly with rotavirus vaccine, reduces rotavirus seroconversion rate

216 global natural intussusception and regional rotavirus vaccine-related risk estimates, and country-sp

217 A monovalent rotavirus vaccine remains effective against a broad rang

218 Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine requiring 2 doses, may have the potent

219 milk secretor status on oral live-attenuated rotavirus vaccine response in breastfed infants has not

220 n and immune activation were correlated with rotavirus vaccine responses in 68 human immunodeficiency

221 should be considered when interpreting oral rotavirus vaccine responses in low- and middle-income se

222 Rotavirus vaccine (Rotarix(R), RV1) has reduced diarrhea

223 an immunological correlate of protection for rotavirus vaccines (Rotarix [RV1] and RotaTeq [RV5]) wou

224 Monovalent rotavirus vaccine, Rotarix (GlaxoSmithKline), was introd

225 The oral infant rotavirus vaccine, Rotarix, was introduced in England an

226 Two rotavirus vaccines, Rotarix (RV1) and RotaTeq (RV5), wer

227 In a monovalent G1P[8] rotavirus vaccine (RotarixTM) trial in Bangladesh, rotav

228 sure surveillance determined that a previous rotavirus vaccine, RotaShield, caused intussusception in

229 to intussusception events noted with a prior rotavirus vaccine, RotaShield.

230 after vaccination with the second-generation rotavirus vaccines RotaTeq (RV5, a pentavalent vaccine)

231 vaccine effectiveness (VE) of a pentavalent rotavirus vaccine (RotaTeq) against rotavirus diarrhea.

232 live, pentavalent, human-bovine reassortant rotavirus vaccine (RotaTeq; Merck) in developed countrie

233 A three-dose, oral rotavirus vaccine (Rotavac) was introduced in the univer

234 ine, a reassortant-tetravalent, rhesus-based rotavirus vaccine (RRV-TV), led to the withdrawal of the

235 nts who received 2 doses of monovalent human rotavirus vaccine (RV1) (days 4, 6, 8, and 10 after vacc

236 a surveillance to evaluate monovalent G1P[8] rotavirus vaccine (RV1) efficacy and understand variable

237 (OPV) is known to interfere with monovalent rotavirus vaccine (RV1) immunogenicity.

238 schedule on the immunogenicity of monovalent rotavirus vaccine (RV1) in a developing country.

239 Botswana introduced monovalent G1P rotavirus vaccine (RV1) in July 2012, providing one of t

240 Kenya introduced monovalent rotavirus vaccine (RV1) in July 2014.

241 protection following vaccination with G1P[8] rotavirus vaccine (RV1) in Malawian infants.

242 After the introduction of monovalent rotavirus vaccine (RV1) in Mexico in 2006-2007, diarrhea

243 irst African nations to introduce monovalent rotavirus vaccine (RV1) into its childhood immunization

244 Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant i

245 A monovalent human rotavirus vaccine (RV1) was introduced in Botswana in Ju

246 sessed the association of the new monovalent rotavirus vaccine (RV1) with intussusception after routi

247 II and III clinical trials of the monovalent rotavirus vaccine (RV1), Rotarix, were analyzed, includi

248 ndomized controlled trial of monovalent oral rotavirus vaccine (RV1).

249 tion (IS) associated with currently licensed rotavirus vaccines (RV1 [Rotarix; GSK] and RV5 [RotaTeq;

250 e association between HBGA status and G3P[6] rotavirus vaccine (RV3-BB) take was investigated in a ph

251 vaccination of U.S. infants with pentavalent rotavirus vaccine (RV5) began in 2006.

252 (HEU) African infants receiving pentavalent rotavirus vaccine (RV5) in a clinical trial.

253 Pentavalent rotavirus vaccine (RV5) was introduced into the Israeli

254 This substudy compared oral rotavirus vaccine (RVV) seroconversion (primary outcome)

255 ssed for oral poliovirus vaccine (OPV), oral rotavirus vaccine (RVV), oral cholera vaccine (OCV), and

256 sk of type 1 diabetes with completion of the rotavirus vaccine series compared to the unvaccinated (9

257 disease in Rwandan children who began their rotavirus vaccine series from 7 to 18 weeks of age.

258 (WHO) recommended that the efficacy of "new" rotavirus vaccines should be demonstrated in diverse geo

259 Both new rotavirus vaccines showed almost identical rates of intu

260 es in Asia and Africa have demonstrated that rotavirus vaccines significantly reduce severe diarrhea

261 Togo introduced monovalent rotavirus vaccine starting 19 June 2014.

262 ographic characteristics, symptom onset, and rotavirus vaccine status were ascertained.

263 We prepared a human rotavirus vaccine strain, CDC-9 (G1P[8]), which when gro

264 of an increased risk of intussusception with rotavirus vaccine, the 14 Latin American countries curre

265 Adding rotavirus vaccine to the national schedule costs Malawi

266 Among 181 Pakistani infants in a G1P[8] rotavirus vaccine trial who were seronegative at baselin

267 The effectiveness of the rotavirus vaccine under conditions of routine use in an

268 terminants including age, geography, season, rotavirus vaccine usage, and symptoms.

269 Rotavirus vaccine use in national immunisation programme

270 d be similar to the risk seen with different rotavirus vaccines used in other countries.

271 The duration of protection offered by rotavirus vaccines varies across the world, and this var

272 ctiveness estimates and absolute benefits of rotavirus vaccines vary through the years following vacc

273 Horizontal transmission of rotavirus vaccine virus may contribute to indirect effec

274 he administration of two doses of monovalent rotavirus vaccine was estimated to be 5.3 per 100,000 in

275 ned among children <5 years of age since the rotavirus vaccine was introduced in 2006; population-lev

276 In Bolivia, monovalent rotavirus vaccine was introduced in 2008 and a previous

277 The monovalent rotavirus vaccine was introduced in Tanzania on 1 Januar

278 Monovalent rotavirus vaccine was introduced in the routine public h

279 f children born after 28 February 2006 (when rotavirus vaccine was licensed in the United States) and

280 Rotavirus vaccine was recommended for US infants in 2006

281 tavirus disease before the introduction of a rotavirus vaccine, we aimed to update the estimated numb

282 Among children age-eligible to receive rotavirus vaccine, we estimated VE, calculated as 1 - od

283 udy of more than 200,000 doses of monovalent rotavirus vaccine, we observed a significant increase in

284 Two live oral rotavirus vaccines were approved by the US Food and Drug

285 Rotavirus vaccines were effective in preventing rotaviru

286 Studies of other infant rotavirus vaccines were excluded because little or no po

287 Rotavirus vaccines were initially introduced in Australi

288 In 2006, 2 rotavirus vaccines were licensed.

289 Although current rotavirus vaccines were not associated with an increased

290 Current rotavirus vaccines were not associated with intussuscept

291 oduction, impact and further developments of rotavirus vaccines were reviewed.

292 Four strains were related to pentavalent rotavirus vaccine, whereas one was related to monovalent

293 Safe, effective rotavirus vaccines will be available soon, and accurate

294 However, it cannot be assumed that rotavirus vaccines will be equally efficacious in infant

295 sception among children receiving monovalent rotavirus vaccine with historical background rates.

296 ne among households whose child had received rotavirus vaccine with those whose child did not receive

297 f 9.5 million infants in these 14 countries, rotavirus vaccine would annually prevent 144 746 (90% co

298 dule versus an unrestricted schedule whereby rotavirus vaccine would be administered with DTP vaccine

299 doses would be given; the first dose of the rotavirus vaccine would be co-administered with either B

300 tly recommended by WHO, but more efficacious rotavirus vaccines would be needed to achieve more subst